Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 15/20 | 0.60 |
| ▸ | CDK9 | P50750 | 15/20 | 0.60 |
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | BCR | P11274 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101900 | 0.86 | ABL1 (0.60) | CCNT1CDK9ABL1BCRMAPT | |
| SCHEMBL4104616 | 0.84 | CCNT1 (0.55) | CCNT1CDK9ABL1BCRTP53 | |
| SCHEMBL4103830 | 0.84 | CCNT1 (0.55) | CCNT1CDK9ABL1BCRTP53 | |
| SCHEMBL4666194 | 0.81 | TP53 (0.61) | CCNT1CDK9ABL1BCRMAPT | |
| SCHEMBL8514905 | 0.79 | CCNT1 (0.61) | CCNT1CDK9ABL1BCRMAPT | |
| SCHEMBL4117234 | 0.79 | ABL1 (0.69) | CCNT1CDK9ABL1BCRMAPT | |
| SCHEMBL6533277 | 0.78 | PIK3CA (0.49) | CCNT1CDK9 | |
| SCHEMBL8515866 | 0.77 | CYP3A4 (0.70) | CCNT1CDK9MAPTTP53KDM4E | |
| SCHEMBL4113685 | 0.76 | BACE1 (0.74) | CCNT1CDK9ABL1BCRKDM4E | |
| SCHEMBL4114071 | 0.75 | CCNT1 (0.67) | CCNT1CDK9ABL1BCRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | CCNT1 81/4885CDK9 97/4885ABL1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.